CVS forged an alliance with the Chicago-based, oncology-focused unicorn to launch the Transform Oncology Program in hopes of spurring precision medicine adoption among a sect of Aetna’s provider network in 12 states, FierceHealthcare reports.

Tempus — which boasts partnerships with leaders in cancer research — leverages its bank of clinical data, machine learning tools, and genomic sequencing to augment clinician understanding of a patient’s cancer to tailor effective treatments.

The program aims to streamline treatment plan design, filter patients who would benefit from genomic sequencing, and assess risk of disease progression. It makes sense for CVS to bet on precision medicine: Now that it has Aetna under its roof, embarking on initiatives that focus on prediction and prevention of cancer — which can become costlier to treat as it progresses — could help beat down spending.

As companies looking to facilitate precision medicine adoption, like Tempus, continue to attract attention from industry players like CVS and investors, we could start to see the needle moving on effective precision medicine applications: No more than 8% of precision medicine interventions in cancer treatment have been successful to date.